In its organising meeting, the Board of Directors of Orion Corporation, which was elected today by the Annual General Meeting of the Shareholders, has elected Timo Maasilta as Vice Chairman.
The compositions of the Board committees were decided to be as follows:
Hannu Syrjänen, Chairman
Heikki Westerlund, Chairman
Sirpa Jalkanen, Chairman
The members to the Nomination Committee were elected on 29 October 2015 as stated in the stock exchange release on the same day.
The Board of Directors has assessed the independence of its members and concluded that all the members are independent of the company and its significant shareholders.
Timo Lappalainen Olli Huotari
President and CEO Senior VP, Corporate Functions
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2015 amounted to EUR 1,016 million and the company had about 3,400 employees. Orion's A and B shares are listed on Nasdaq Helsinki.